Fulcrum Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Name: Fulcrum Therapeutics Inc: Is Infosys Ltd. worth buying?
Item: Fulcrum Therapeutics Inc
Rating: 1.03975
Author: Trendlyne DVM scores

about

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) ...

6.69 -0.42 (-5.91%)

57.50% Fall from 52W High

431.1K

XNAS Volume

XNAS 15 May, 2026 5:30 PM (EDT)

Not Eligible

Expensive Valuation

12.0 / 100

Technically Bearish

29.6 / 100

1Yr Price target upside is 184%

10 analysts

Fulcrum Therapeutics Inc Live Price Chart

Switch to TradingView

Loading Fundamental data..

Loading data..

Fulcrum Therapeutics Inc Live Stock Price Today, Share Analysis and Chart

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) ...

57.50% Fall from 52W High

SWOT Analysis

Fulcrum Therapeutics Inc Live Price Chart